BioSpace9d
Neurocrine’s Takeda-Partnered Drug Candidate Aces Phase II Depression Study
An undisclosed once-daily oral dose of Neurocrine Biosciences’ Takeda-partnered investigational drug significantly reduced ...
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced positive topline data for its Phase 2 SAVITRI™ study. This randomized, double-blind, placebo-controlled dose-finding study assessed the ...
FierceBiotech9d
Neurocrine-Takeda med reduces depression severity in phase 2, though analysts ask for more data detail
Neurocrine Biosciences has nabbed a phase 2 win, with its investigational med in-licensed from Takeda significantly reducing ...
Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data
Neurocrine achieved positive results achieved from phase 2 SAVITRI study for the treatment of patients with MDD. Check out ...
Investing10d
Neurocrine reports promising phase 2 depression drug data
NBI-1065845 is an alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) positive allosteric modulator (PAM) and is part of a strategic collaboration with Takeda (TSE:4502/NYSE ...
Neurocrine Biosciences, Inc.: Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
SAVITRI Study Met Primary Endpoint with Statistically Significant Reduction in Montgomery Åsberg Depression Rating Scale (MADRS) Total Score at Day 28 Met Key Secondary Endpoints, Including Statistica ...